



AMENDMENTS TO THE CLAIMS:

1. (Currently Amended) A method for treating a CNS disorder or impaired cognitive performance in a subject comprising administering to said subject in need thereof an effective amount of a pharmaceutical composition comprising a compound or a stereoisomer, pharmaceutically acceptable salt, solvate or polymorph thereof according to the structure:



(I)

or



(II)

wherein:

R^1 and R^2 are independently selected from H, C_1 - C_3 alkyl, F, Cl, Br, I, OH, $O(C_1$ - C_6 alkyl), $O-C(=O)-(C_1$ - C_6 alkyl) or $C(=O)-O-(C_1$ - C_6 alkyl);

R^3 is H or a C_1 - C_6 alkyl group;

R^4 , R^5 , R^6 , R^7 and R^8 are independently selected from H, C_1 - C_6 alkyl, F, Cl, Br, I, OH, $-(CH_2)_nO(C_1$ - C_6 alkyl), $-(CH_2)_nO-C(=O)-(C_1$ - C_6 alkyl) or $-(CH_2)_nC(=O)-O-(C_1$ - C_6 alkyl);

R^9 and R^{10} are independently H, C_1 - C_6 alkyl or together form a $-(CH_2)_m$ - group to produce a 5-7 membered ring;

N is from 0 to 5;

M is from 0 to 3;

and A^- A^- is a pharmaceutically acceptable anion of a pharmaceutical salt, which forms a salt with the quaternized amine group, optionally in combination with a pharmaceutically acceptable carrier, additive or excipient.

2. (Original) A method of claim 1 wherein R^1 and R^2 are both OCH_3 groups, R^3 is a CH_3 group, R^4 , R^5 , R^6 , R^7 and R^8 are each H, R^9 and R^{10} are each H, CH_3 or together form a $-CH_2-$ group to produce a five-membered ring; and A^- is Cl^- , citrate or phosphate.

3. (Original) A method of claim 2, wherein R^9 and R^{10} together form a $-CH_2-$ group to produce a five-membered ring.

4. (Original) A method of claim 1, wherein the CNS disorder is a bipolar disorder.
5. (Original) A method of claim 1, wherein the CNS disorder is an anxiety disorder.
6. (Original) A method of claim 1, wherein the CNS disorder is stress-induced.
7. (Currently Amended) A method of claim 1, wherein the CNS disorder is attention deficit hyperactivity disorder (ADHD).
8. (Original) A method of claim 1, wherein the CNS disorder is schizophrenia.
9. (Original) A method of claim 1, wherein said subject is treated for impaired cognitive performance.
10. (Original) A method of claim 1, wherein the CNS disorder is associated with enhanced PKC activity.
11. (Original) A method of claim ~~19~~, wherein the impaired cognitive performance is induced or exacerbated by stress.
12. (Original) A method of claim 1, wherein the pharmaceutical composition is administered orally and the subject is a human.
13. (Original) A method of claim 9, wherein the pharmaceutical composition is administered orally and the subject is a human.
14. (Original) A method of claim 10, wherein the pharmaceutical composition is administered orally and the subject is a human.
- 15.-17. (Canceled)
18. (Original) A method of treatment comprising administering to a subject suffering from

manic episodes associated with enhanced PKC activity a therapeutically effective amount of a composition according to claim 15.

19. (Original) A method of claim 18, wherein the manic episodes are also stress induced.

20. (Original) A method comprising protecting a subject from developing a CNS disorder by administering to the subject a therapeutically effective amount of a pharmaceutical composition according to claim 15.

21. (New) A method of Claim 1, wherein the CNS disorder is bipolar disorder, schizophrenia, an anxiety disorder, impaired cognitive performance, or attention deficit hyperactivity disorder (ADHD).